2. Metabolic Enzyme/Protease Apoptosis Immunology/Inflammation
  3. Phosphodiesterase (PDE) Bcl-2 Family NO Synthase Apoptosis
  4. PDE4B/D-IN-5

PDE4B/D-IN-5 (Compound P32) is a peripherally restricted, oral active inhibitor of PDE4B and PDE4D with extremely low blood-brain barrier penetration, with IC50 values of 3.4 nM and 2.2 nM, respectively. PDE4B-IN-8 inhibits the production of TNF-α. PDE4B/D-IN-5 significantly reduces the Bax/Bcl2 ratio, and alleviates oxidative stress by decreasing MPO activity and NO levels. PDE4B/D-IN-5 exhibits anti-inflammatory, antioxidant, and anti-apoptotic activities. PDE4B/D-IN-5 can be used for the research of acute lung injury.

For research use only. We do not sell to patients.

PDE4B/D-IN-5

PDE4B/D-IN-5 Chemical Structure

CAS No. : 3064814-26-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

PDE4B/D-IN-5 Related Antibodies

Top Publications Citing Use of Products

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms
PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PDE4B/D-IN-5 (Compound P32) is a peripherally restricted, oral active inhibitor of PDE4B and PDE4D with extremely low blood-brain barrier penetration, with IC50 values of 3.4 nM and 2.2 nM, respectively. PDE4B-IN-8 inhibits the production of TNF-α. PDE4B/D-IN-5 significantly reduces the Bax/Bcl2 ratio, and alleviates oxidative stress by decreasing MPO activity and NO levels. PDE4B/D-IN-5 exhibits anti-inflammatory, antioxidant, and anti-apoptotic activities. PDE4B/D-IN-5 can be used for the research of acute lung injury[1].

IC50 & Target[1]

PDE4B1

3.4 nM (IC50)

PDE4D3

2.2 nM (IC50)

In Vitro

PDE4B/D-IN-5 potently inhibits recombinant PDE4B1 in an in vitro fluorescence polarization enzyme activity assay (IC50 = 3.4 nM)[1].
PDE4B/D-IN-5 (15 μM; up to 90 min) exhibits high metabolic stability in rat liver microsomes, with 94.8% remaining after 60 min, a half-life of 5.5 h, and a clearance as low as 0.0021 mL min−1 mg−1[1].
PDE4B/D-IN-5 (1-4 μM; 1 h) dose-dependently inhibits LPS-stimulated TNF-α production in RAW264.7 mouse macrophages[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PDE4B/D-IN-5 Related Antibodies

ELISA Assay[1]

Cell Line: RAW264.7 murine macrophages
Concentration: 1-4 μM
Incubation Time: 1 h
Result: Reduced supernatant TNF-α levels in a dose-dependent manner compared to the LPS-induced model group (which had TNF-α levels of 26 pg/mL, vs baseline 9 pg/mL in untreated cells).
Parmacokinetics
Species Dose Route Tmax Cmax AUC0-t AUC0-∞ T1/2 MRT
Mice[1] 1 (plasma) mg/kg i.v. 4.98 min 7665.53 ng/mL 5661.94 ng·h/mL 5735.78 ng·h/mL 1.26 h 1.09 h
Mice[1] 25 (plasma) mg/kg p.o. 36 min 46941.22 ng/mL 111577.48 ng·h/mL 127646.89 ng·h/mL 2.45 h 3.40 h
Mice[1] 1 (brain) mg/kg i.v. 9.98 min 49.69 ng/mL 73.90 ng·h/mL 80.96 ng·h/mL 2.07 h 2.71 h
In Vivo

PDE4B/D-IN-5 (1-6 mg/kg; p.o.; single dose) does not induce emesis in beagle dogs[1].
PDE4B/D-IN-5 (6-12 mg/kg; i.p.; daily; 5 days) dose-dependently attenuates LPS-induced acute lung injury in male C57BL/6 mice via anti-inflammatory, antioxidant, and antiapoptotic effects mediated by the cAMP-Epac pathway[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (male, 8 weeks old, acute lung injury model via intratracheal LPS instillation)[1]
Dosage: 6 mg/kg; 12 mg/kg
Administration: i.p.; daily; 5 days
Result: Reduced lung erythema, enlargement, alveolar damage, interstitial edema, and inflammatory cell infiltration.
Showed a significant reduction in Smith lung injury scores in the 12 mg/kg group compared to the model group.
Reduced lung wet/dry weight ratios with a dose-dependent trend.
Reduced bronchoalveolar lavage fluid (BALF) neutrophil counts more effectively than dexamethasone, with a dose-dependent effect.
Attenuated lung myeloperoxidase (MPO) activity more potently than dexamethasone, with a dose-dependent effect.
Reduced lung tissue nitric oxide (NO) levels to values comparable to dexamethasone.
Suppressed BALF tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) levels in a dose-dependent manner, with the 12 mg/kg group showing greater suppression than dexamethasone.
Dose-dependently elevated lung tissue cAMP levels, with the 12 mg/kg group showing the most pronounced effect.
Induced a dose-dependent, significant upregulation of Epac1 protein expression.
Significantly decreased the Bax/Bcl2 ratio, indicating suppression of mitochondrial apoptosis.
Showed no statistically significant changes in p-PKA/PKA or p-AMPK/AMPK ratios.
Molecular Weight

425.43

Formula

C22H21F2N5O2
CAS No.
SMILES

FC([H])(CN1N=C(C2=CC=NN2CC)C3=C1C=CC(NC4=CC=C(CC(O)=O)C=C4)=C3)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PDE4B/D-IN-5 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PDE4B/D-IN-53064814-26-9Phosphodiesterase (PDE)Bcl-2 FamilyNO SynthaseApoptosisNitric oxide synthasesNOSPDE4D3cyclic adenosine monophosphateRAW264.7 cellscAMP-Epac pathwayC57BL/6 miceacute lung injuryrat hepatic microsomesPDE4B1tumor necrosis factor-αPDE4BInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PDE4B/D-IN-5
Cat. No.:
HY-182060
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.